

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCT SEMAGLUTIDE INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 25 October 2022, The United Bio-Technology (Hengqin) Co., Ltd. ("The United Bio-Technology"), a wholly-owned subsidiary of the Company, received the Notice of Approval of Clinical Trial (Reference No.: CXSL2200379) issued by China National Medical Products Administration regarding Semaglutide Injection applied by The United Bio-Technology.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes. Semaglutide is the most effective blood-glucose-reduction GLP-1 analogue among the same target drugs existing in the market. It only requires to be injected once a week, and is characterized by safety, simplicity and significant efficacy. By promoting the secretion of insulin by pancreatic cells, it can significantly reduce the blood glucose in vivo, reduce the weight of the patients and show obvious cardiovascular benefits. In addition to the indication of type 2 diabetes, several indications including weight loss, non-alcoholic steatohepatitis (NASH) and Alzheimer's disease are currently under research.

The approval will further enrich the Company's product portfolio in the field of diabetes treatment and accelerate the Company's strategic layout in the field of chronic diseases. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 26 October 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.